Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Last trade$3.92
Day change+$0.075 (+1.95%)
Day range$3.77 – $3.98
Volume3,496,802
Market cap$1.36B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.36B
Price / earnings
—
Price / book
5.95×
Price / sales
6.72×
EV / sales
7.45×
EV / EBITDA
-12.46×
Profitability
Earnings per share
-$0.39
Return on assets
-17.46%
Return on equity
-59.63%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.32×
Current ratio
7.45×
Quick ratio
7.3×
Cash ratio
1.56×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$108.17M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NUVB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$44.95M
$31.69M
$83.23M
$41.87M
$13.12M
$4.83M
$3.08M
$5.71M
Cost of revenue
$9.81M
$8.56M
$5.62M
$423K
$3.01M
$2.4M
$2.09M
$4.22M
Gross profit
$35.14M
$23.13M
$77.61M
$41.44M
$10.11M
$2.43M
$990K
$1.5M
Selling, general and administrative
$44.67M
$43.5M
$38.68M
$40.63M
$37.69M
$38.66M
$35.39M
$25.39M
Research and development
$32.68M
$30.66M
$35.05M
$34.3M
$28.85M
$27.36M
$24.6M
$29.3M
Total operating expenses
$77.35M
$74.16M
$73.73M
$74.92M
$66.54M
$66.02M
$59.99M
$54.69M
Operating income
-$42.21M
-$51.04M
$3.88M
-$33.48M
-$56.43M
-$63.59M
-$59M
-$53.19M
Interest expense
-$6.12M
-$6.76M
-$6.71M
-$6.67M
-$6.53M
-$421K
-$54K
-$89K
Income before taxes
-$41.9M
-$62.84M
$5.4M
-$36.59M
-$55.79M
-$59.01M
-$53.24M
-$49.45M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$41.9M
-$62.84M
$5.4M
-$36.59M
-$55.79M
-$59.01M
-$53.24M
-$49.45M
Net income attributable to common shareholders
-$41.9M
-$62.84M
$5.4M
-$36.59M
-$55.79M
-$59.01M
-$53.24M
-$49.45M
EBITDA
-$41.63M
-$50.5M
$4.42M
-$32.94M
-$55.9M
-$63.23M
-$58.69M
-$52.97M
Basic earnings per share
-$0.12
-$0.18
$0.02
-$0.11
-$0.16
-$0.17
-$0.16
-$0.15
Diluted earnings per share
-$0.12
-$0.18
$0.01
-$0.11
-$0.16
-$0.17
-$0.16
-$0.15
Recent news
Company coverage with links to the original publishers.
Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.
Nuvation Bio reported a quarterly loss of $0.12 per share, missing the consensus estimate of $0.11 loss, representing a -9.09% earnings surprise. However, the company exceeded revenue expectations with $44.95 million, surpassing estimates by 32.33% and showing 242% year-over-year growth. The stock has underperformed significantly, down 47.7% year-to-date versus the S&P 500's 10.6% gain. Zacks assigned the stock a Hold rating (Rank #3) with mixed estimate revision trends.
Nuvation Bio's Chief People Officer Stacy Markel sold 125,000 shares worth $753,000 on June 23, 2026, reducing her direct holdings by 79.32%. However, the sale was executed under a pre-established trading plan adopted in December 2025, and Markel retains significant exposure through 629,810 outstanding options. Despite the stock's 190% surge over the past year and recent 40% pullback from December highs, the article suggests investors should focus more on the company's ability to convert regulatory wins into commercial growth, particularly with taletrectinib's global launch.
Robert Mashal, an oncology-trained director at Nuvation Bio, purchased 25,000 shares at $4.73 per share on June 9, 2026, bringing his total indirect holdings to 225,000 shares. The purchase comes as Nuvation's first FDA-approved cancer drug, Ibtrozi, continues gaining traction with over 200 new patients per quarter since its July 2025 launch. The stock has surged 96% over the past year, and Wall Street projects revenue will nearly triple to $203 million in 2026.
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 Class A shares for approximately $904,000 on April 6, 2026, reducing his direct holdings by 79%. However, he retains 53,000 shares and 700,000 stock options, suggesting the sale is a routine profit-taking exercise rather than a loss of confidence in the company. Nuvation Bio, a clinical-stage oncology biotech with promising pipeline candidates, reported a net loss of $204.6 million but this is typical for R&D-heavy biotech firms.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.